Ligand Pharmaceuticals Incorporated (LGND) financial statements and ratios from SEC XBRL: revenue $0.3B (TTM), net margin 46.4%, revenue growth 33.7% YoY, P/E 41.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $268.09M |
| Revenue (TTM) | $0.3B |
| Net Margin | 46.4% |
| Operating Margin (TTM) | 49.9% |
| Net Debt / EBITDA | 0.7 |
| Revenue Growth (YoY) | 33.7% |
| EPS Growth (YoY) | 868.0% |
| FCF Growth (YoY) | -819.2% |
| P/E Ratio | 41.0 |
| EV / EBITDA | 37.2 |
| Price / Book | 5.89 |
| Price / Sales | 20.18 |
| FCF Yield | 3.0% |
| Altman Z-Score | 7.71 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
LGND overview · LGND earnings · LGND KPIs · LGND documents · LGND ownership · LGND peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.